Summit Therapeutics appoints Dr. Maky Zanganeh as Co-CEO & President

Summit Therapeutics Inc.

Dr. Maky Zanganeh appointed Co-CEO & President effective July 25, 2022; formerly COO.
Bob Duggan remains Chairman of the Board and CEO, co-leading with Zanganeh.
Zanganeh previously COO at Pharmacyclics; led key deals including $21B sale to AbbVie and $1B ibrutinib collaboration.
She has been on Summit's board since November 2020 and continues to serve.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Dr. Maky Zanganeh

Co-Chief Executive Officer and President

SMMT · Summit Therapeutics Inc.

Effective: 2022-07-25
Filed: July 26, 2022, 7:59 PM ET

Effective July 25, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Dr. Maky Zanganeh to serve as Co-Chief Executive Officer and President of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Maky Zanganeh was appointed as Co-Chief Executive Officer and President at Summit Therapeutics Inc..

Action: appointed
Role: Co-Chief Executive Officer and President

Exact text from the filing

Effective July 25, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Dr. Maky Zanganeh to serve as Co-Chief Executive Officer and President of the Company.

View on SEC.gov

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-22-000084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.